Recent Clinical Trials of Immunotherapy in Non-Small-cell Lung Cancer.
Stavros Gkolfinopoulos,Giannis Mountzios
DOI: https://doi.org/10.2217/imt-2019-0021
2019-01-01
Immunotherapy
Abstract:ImmunotherapyVol. 11, No. 6 CommentaryRecent clinical trials of immunotherapy in non-small-cell lung cancerStavros Gkolfinopoulos & Giannis MountziosStavros Gkolfinopoulos Medical Oncology Department, BOC Oncology Center, Nicosia 2006, Cyprus & Giannis Mountzios*Author for correspondence: Tel.: +30 69 83 51 99 89; Fax: +30 21 07 78 11 04; E-mail Address: gmountzios@gmail.com 2nd Medical Oncology Department, Henry Dunant Hospital Center, Athens 11526, GreecePublished Online:12 Mar 2019https://doi.org/10.2217/imt-2019-0021AboutSectionsView ArticleView Full TextPDF/EPUB ToolsAdd to favoritesDownload CitationsTrack CitationsPermissionsReprints ShareShare onFacebookTwitterLinkedInReddit View articleKeywords: atezolizumabavelumabcheckpoint inhibitorsdurvalumabipilimumabnivolumabnon-small-cell lung cancerpembrolizumabReferences1 Schiller JH, Morgan-Ihrig C, Levitt ML. Concomitant administration of interleukin-2 plus tumor necrosis factor in advanced non-small-cell lung cancer. Am. J. Clin. Oncol. 18, 47–51 (1995).Crossref, Medline, CAS, Google Scholar2 Jansen RL, Slingerland R, Goey SH et al. Interleukin-2 and interferon-alpha in the treatment of patients with advanced non-small-cell lung cancer. J. Immunother. 12, 70–73 (1992).Crossref, Medline, CAS, Google Scholar3 Borghaei H, Paz-Ares L, Horn L et al. Nivolumab versus Docetaxel in advanced nonsquamous non-small-cell lung cancer. N. Engl. J. Med. 373(17), 1627–1639 (2015).Crossref, Medline, CAS, Google Scholar4 Brahmer J, Reckamp KL, Baas P et al. Nivolumab versus Docetaxel in advanced squamous-cell non-small-cell lung cancer. N. Engl. J. Med. 373(2), 123–135 (2015).Crossref, Medline, CAS, Google Scholar5 Herbst RS, Baas P, Kim DW et al. Pembrolizumab versus docetaxel for previously treated, PD-L1-positive, advanced non-small-cell lung cancer (KEYNOTE-010): a randomised controlled trial. Lancet 387(10027), 1540–1550 (2016).Crossref, Medline, CAS, Google Scholar6 Rittmeyer A, Barlesi F, Waterkamp D et al. Atezolizumab versus docetaxel in patients with previously treated non-small-cell lung cancer (OAK): a Phase III, open-label, multicentre randomised controlled trial. Lancet 389(10066), 255–265 (2017).Crossref, Medline, Google Scholar7 Reck M, Rodríguez-Abreu D, Robinson AG et al. Pembrolizumab versus chemotherapy for PD-L1-positive non-small-cell lung cancer. N. Engl. J. Med. 375(19), 1823–1833 (2016).Crossref, Medline, CAS, Google Scholar8 Lopes G, Wu Y-L, Kudaba I et al. Pembrolizumab (pembro) versus platinum-based chemotherapy (chemo) as first-line therapy for advanced/metastatic NSCLC with a PD-L1 tumor proportion score (TPS)≥1%: open-label, Phase III KEYNOTE-042 study. J. Clin. Oncol. 36(18 Suppl), LBA4 (2018).Crossref, Google Scholar9 Naiyer Rizvi, Fabrice Barlesi, Julie Brahmer et al. Phase III, randomized, open-label study of durvalumab (MEDI4736) in combination with tremelimumab or durvalumab alone versus platinum-based chemotherapy in first-line treatment of patients with advanced/metastatic NSCLC: MYSTIC. J. Immunother. Cancer 3(Suppl. 2), P171 (2015).Google Scholar10 First line immunotherapy combination fails to improve overall survival in lung cancer [ESMO Press Release]. ESMO Immuno-Oncology Congress 13 Dec (2018). www.esmo.org/Press-Office/Press-Releases/Mystic-immunotherapy-nsclc-rizviGoogle Scholar11 Barlesi F, Vansteenkiste J, Spigel D et al. Avelumab versus docetaxel in patients with platinum-treated advanced non-small-cell lung cancer (JAVELIN Lung 200): an open-label, randomised, Phase III study. Lancet Oncol. 19(11), 1468–1479 (2018).Crossref, Medline, CAS, Google Scholar12 Hellmann MD, Ciuleanu TE, Pluzanski A et al. Nivolumab plus Ipilimumab in lung cancer with a high tumor mutational burden. N. Engl. J. Med. 378(22), 2093–2104 (2018).Crossref, Medline, CAS, Google Scholar13 Carbone DP, Reck M, Paz-Ares L et al. First-line nivolumab in stage IV or recurrent non-small-cell lung cancer. N. Engl. J. Med. 376(25), 2415–2426 (2017).Crossref, Medline, CAS, Google Scholar14 Hellmann MD, Callahan MK, Awad MM et al. Tumor mutational burden and efficacy of nivolumab monotherapy and in combination with Ipilimumab in small-cell lung cancer. Cancer Cell 33(5), 853–861 (2018).Crossref, Medline, CAS, Google Scholar15 Yarchoan M, Hopkins A, Jaffee EM. Tumor mutational burden and response rate to PD-1 inhibition. N. Engl. J. Med. 377, 2500–2501 (2017).Crossref, Medline, Google Scholar16 Powles T, Loriot Y, Ravaud A et al. Atezolizumab vs chemotherapy in platinum-treated locally advanced or metastatic urothelial carcinoma: immune biomarkers, tumor mutational burden and clinical outcomes from the Phase III IMvigor211 study. Presented at: The 2018 Genitourinary Cancers Symposium, San Francisco, CA, USA, 8–10 February 2018).Google Scholar17 Ramalingam SS, Hellmann MD, Awad MM et al. Tumor mutation burden (TMB) as a biomarker for clinical benefit from dual immune checkpoint blockade with nivolumab (nivo) + ipilimumab (ipi) in first-line (1L) non-small cell lung cancer (NSCLC): identification of TMB cutoff from CheckMate 568. Presented at: The American Association for Cancer Research 2018 Annual Meeting, Chicago, IL, USA, 16 April 2018.Google Scholar18 Gandhi L, Rodríguez-Abreu D, Gadgeel S et al. Pembrolizumab plus chemotherapy in metastatic non-small-cell lung cancer. N. Engl. J. Med. 378(22), 2078–2092 (2018).Crossref, Medline, CAS, Google Scholar19 Kowanetz M, Zou W, McCleland M et al. Pre-existing immunity measured by Teff gene expression in tumor tissue is associated with atezolizumab efficacy in NSCLC. J. Thorac. Oncol. 12(Suppl. 2), S1817–S1818 abstract (2017).Crossref, Google Scholar20 Socinski MA, Jotte RM, Cappuzzo F et al. Atezolizumab for first-line treatment of metastatic nonsquamous NSCLC. N. Engl. J. Med. 378(24), 2288–2301 (2018).Crossref, Medline, CAS, Google ScholarFiguresReferencesRelatedDetailsCited ByRecent developments and challenges in the molecular targeted therapies of non-small cell lung cancerJournal of Environmental Pathology, Toxicology and OncologyNanomedicine in Non-Small Cell Lung Cancer: From Conventional Treatments to Immunotherapy18 June 2020 | Cancers, Vol. 12, No. 6Current Perspectives in Cancer Immunotherapy30 September 2019 | Cancers, Vol. 11, No. 10 Vol. 11, No. 6 Follow us on social media for the latest updates Metrics Downloaded 229 times History Received 24 January 2017 Accepted 7 February 2018 Published online 12 March 2019 Published in print April 2019 Information© 2019 Future Medicine LtdKeywordsatezolizumabavelumabcheckpoint inhibitorsdurvalumabipilimumabnivolumabnon-small-cell lung cancerpembrolizumabFinancial & competing interests disclosureThe authors declare consultancies and honoraria from Roche Hellas, BMS Greece, MSD Greece, Boehringer-Ingelheim Greece, Pierre Fabre, Takeda Hellas, Pfizer Greece and Astra-Zeneca Greece. The authors have no other relevant affiliations or financial involvement with any organization or entity with a financial interest in or financial conflict with the subject matter or materials discussed in the manuscript apart from those disclosed.No writing assistance was utilized in the production of this manuscript.PDF download